ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 2533

Are There Differences in Baseline Comorbidities Between Rheumatoid Arthritis Patients Treated with Abatacept and Those Treated with Tumor Necrosis Factor Inhibitors?

M. Victoria Hernández1, Carlos Sánchez-Piedra2, Jose Inciarte-Mundo1, Fernando Sanchez-Alonso2, Javier Manero3, Rosa Roselló4, Eva Pérez-Pampin5, Carlos Rodriguez-Lozano6, Cesar Diaz-Torné7, Raimon Sanmarti1, Juan J. Gómez-Reino5 and Biobadaser 2.0 Study Group, 1Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, 2Research Unit, Spanish Society of Rheumatology, Madrid, Spain, 3Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, 4Rheumatology, H San Jorge, Huesca, Spain, 5Rheumatology, Hospital Clínico Universitario. Santiago de Compostela, Santiago de Compostela, Spain, 6Rheumatology, Hospital de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain, 7Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: , , ,

Session Information

Date: Tuesday, November 15, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:  Rheumatoid arthritis (RA) patients frequently report concomitant comorbidities that could worsen their prognosis. Tumor necrosis factor inhibitors (TNFi), the most common biological agents used, have shown efficacy in RA patients, although use in RA patients with certain comorbidities warrant caution (1). Abatacept, a biologic agent with a different mechanism of action, inhibiting the co-stimulation of the T-lymphocyte, has demonstrated differentiated safety profile (2), that could influence the biological agent prescribed in RA patients with some associated comorbidities. Our objective is to analyze differences in the frequency of baseline comorbidities in RA patients treated with abatacept compared with those treated with TNFi

Methods: Patients with RA recruited into the BIOBADASER 2.0 register from January 2008 to December 2014 and treated with abatacept or TNFi with comorbidities were selected. Comorbidity was defined as ≥ 1 of the following at initiation of biological therapy: Ischemic heart disease; lymphoma; malignancy (except lymphoma); diabetes; chronic pulmonary obstructive disease (CPOD); smoking; hypercholesterolemia; hypertension; heart failure; renal failure; osteoporosis; Epstein Barr, hepatitis B or C virus infection; and others. We analyzed the frequency of each comorbiditiy and the differences in the rate of baseline comorbidities between the two groups

Results:  From January 2008 to December 2014, 640 and 252 RA patients treated respectively with TNFi or abatacept, were included in the BIOBADASER 2.0 register, of whom 51.6% had ≥ 1 comorbitity at baseline. Frequencies for every basal comorbidity described ere shown in Table 1. There was a significantly higher rate of heart failure in abatacept than in TNFi patients. Other comorbidities showed no significant differences Table 1

Frequency (%)

Comorbidities

Abatacept

TNFi

p-value

Ischemic heart disease

1(2.3)

14(2.1)

0.940

Malignancy (except lymphoma)

1(2.3)

13(1.9)

0.883

Diabetes

6(13.6)

46(6.9)

0.098

CPOD

2(4.6)

16(2.4)

0.382

Smoking

8(18.2)

109(16.4)

0.757

Hypercholesterolemia

9(20.4)

111(16.7)

0.519

Hypertension

10(22.7)

148(22.3)

0.942

Epstein Barr infection

0(0)

1(0.1)

0.797

Heart failure

4(9.1)

6(0.9)

<0.001

Renal failure

0(0)

8(1.2)

0.464

Lymphoma

0(0)

0(0)

Osteoporosis

7(15.9)

89(13.4)

0.635

Hepatitis B virus infection

1(2.3)

13(1.9)

0.883

Hepatitis C virus infection

0(0)

1(0.1)

0.797

Others

22(50)

292(43.9)

0.431

Conclusion:  RA patients treated with abatacept had a higher baseline frequency of concomitant heart failure compared with patients treated with TNFi, probably reflecting different recommendations on biological drug use. No differences in other baseline comorbidities were found between groups References: (1) Singh et al. Arthritis Rheum 2016; 68: 1–26. (2) Singh et al. Cochrane Database Syst Rev. 2011; 16: CD008794

Disclosure: M. V. Hernández, None; C. Sánchez-Piedra, None; J. Inciarte-Mundo, None; F. Sanchez-Alonso, None; J. Manero, None; R. Roselló, None; E. Pérez-Pampin, None; C. Rodriguez-Lozano, None; C. Diaz-Torné, None; R. Sanmarti, None; J. J. Gómez-Reino, None.

To cite this abstract in AMA style:

Hernández MV, Sánchez-Piedra C, Inciarte-Mundo J, Sanchez-Alonso F, Manero J, Roselló R, Pérez-Pampin E, Rodriguez-Lozano C, Diaz-Torné C, Sanmarti R, Gómez-Reino JJ. Are There Differences in Baseline Comorbidities Between Rheumatoid Arthritis Patients Treated with Abatacept and Those Treated with Tumor Necrosis Factor Inhibitors? [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/are-there-differences-in-baseline-comorbidities-between-rheumatoid-arthritis-patients-treated-with-abatacept-and-those-treated-with-tumor-necrosis-factor-inhibitors/. Accessed .

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/are-there-differences-in-baseline-comorbidities-between-rheumatoid-arthritis-patients-treated-with-abatacept-and-those-treated-with-tumor-necrosis-factor-inhibitors/